Shandong Kexing Bioproducts Co,.Ltd (688136.SS)
CNY 20.64
(5.84%)
CNY 20.64
(5.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -119.68 Million CNY | -274.05% |
| 2022 | -28.86 Million CNY | -133.86% |
| 2021 | 164.81 Million CNY | -47.69% |
| 2020 | 209.74 Million CNY | -11.56% |
| 2019 | 213.89 Million CNY | 40.75% |
| 2018 | 143.81 Million CNY | 60.32% |
| 2017 | 89.65 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 19.22 Million CNY | -69.43% |
| 2024 Q1 | 30.14 Million CNY | 126.19% |
| 2024 Q2 | 75.93 Million CNY | 52.92% |
| 2023 Q2 | -67.3 Million CNY | -810.2% |
| 2023 FY | - CNY | -274.05% |
| 2023 Q3 | 9.88 Million CNY | 114.68% |
| 2023 Q1 | -7.39 Million CNY | 80.9% |
| 2023 Q4 | -157 Million CNY | -1688.57% |
| 2022 Q3 | -70.67 Million CNY | -145.07% |
| 2022 Q2 | -28.83 Million CNY | -191.59% |
| 2022 Q1 | 31.48 Million CNY | 228.18% |
| 2022 FY | - CNY | -133.86% |
| 2022 Q4 | -38.72 Million CNY | 45.21% |
| 2021 FY | - CNY | -47.69% |
| 2021 Q3 | 15.23 Million CNY | 53.03% |
| 2021 Q4 | -24.56 Million CNY | -261.22% |
| 2021 Q1 | 54.94 Million CNY | 70.22% |
| 2021 Q2 | 9.95 Million CNY | -81.88% |
| 2020 Q3 | 38.81 Million CNY | 637.97% |
| 2020 FY | - CNY | -11.56% |
| 2020 Q4 | 32.27 Million CNY | -16.85% |
| 2020 Q2 | 5.25 Million CNY | -95.33% |
| 2020 Q1 | 112.68 Million CNY | 79.54% |
| 2019 Q3 | -400.56 Million CNY | 0.0% |
| 2019 FY | - CNY | 40.75% |
| 2019 Q4 | 62.76 Million CNY | 115.67% |
| 2018 FY | - CNY | 60.32% |
| 2017 FY | - CNY | 0.0% |